UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000001312 |
|---|---|
| Receipt number | R000001593 |
| Scientific Title | Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer |
| Date of disclosure of the study information | 2008/08/12 |
| Last modified on | 2017/01/13 13:37:26 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer
Acronym
Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer(KSCC0801)
Scientific Title
Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer
Scientific Title:Acronym
Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer(KSCC0801)
Region
| Japan |
Condition
Condition
Unresectable advanced/recurrent colorectal cancer
Classification by specialty
| Gastroenterology | Hepato-biliary-pancreatic medicine | Hematology and clinical oncology |
| Gastrointestinal surgery | Hepato-biliary-pancreatic surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
PFS
Key secondary outcomes
Response rate,
Safety,
OS
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1.colorectal cancer, cytologically and/or histrogically
2.Unresectable advanced/recurrent colorectal cancer
3.no prior chemotherapy
4.no prior radiotherapy
5.age: 20-75 years old
6. Performance Status(ECOG):0-2
7.with measurable lesions
8.CT/MRI within 28 days
9.Life expectancy estimated >= 3 months
10.no bleeding tendency
11.Sufficient organ functions
12.witten informed consents
Key exclusion criteria
1. Administering antithrobotic drug within 7 days
2. Serious complications (renal failure or hepatic failure)
3. Serious drug hypersensitivity or a history of drug allergy
4. Peripheral neuropathy
5. Active concomitant malignancy
6. Active infections
7. High blood pressure and diabetic that cannot be controlled
8. symptomatic or asymptomatic but treated heart disease
9. interstitial pnumonitis, pulmonary fibrosis or high-grade pulmonary emphysema
10. histry of mental disturbances or cerebrovascular attach
11. Fresh hemorrhage from digestive tube, intestines tube paralysis, intestinal obstruction and peptic ulcer
12. Current or previous (within one year) history of GI perforation
13. Plerral effusion, peritoneal fluid and pericardial fluid
14. Symptomatic brain metastasis
15. Water solubility diarrhea, in case of the patient who has a colostomy, diarrhea impairs daily life activity
16. Need to treatment with atazanavir sulfate
17. under coutinuous steroid therapy
18. Any surgical treatments including skin-open biopsy, trauma surgery and other more intensive surgery within 4 weeks or aspiration biopsy within one week
19. CV-port procedure within one week
20. Anti-platelets therapy (including aspirin and NSAIDS)
21. history of organ transplantation
22. Traumatic gracture of unrecovery
23. Bevacizumab used previous chemotherapy
24. Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers
25. Other conditions not suitable for this study
Target sample size
51
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Maehara Yoshihiko |
Organization
Kyushu University
Division name
Dpt. of surgery and science
Zip code
Address
Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582
TEL
092-631-2920
info2@cres-kyushu.or.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | KSCC |
Organization
CReS
Division name
KSCC
Zip code
Address
Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582
TEL
092-631-2920
Homepage URL
kscc2@cres-kyushu.or.jp
Sponsor or person
Institute
KSCC
Institute
Department
Personal name
Funding Source
Organization
CReS
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
九州大学（福岡県）
国立病院機構九州医療センター（福岡県）
公立学校共済組合九州中央病院（福岡県）
済生会福岡総合病院（福岡県）
福岡歯科大学医科歯科総合病院（福岡県）
済生会八幡総合病院（福岡県）
新日鐵八幡記念病院（福岡県）
社会保険田川病院（福岡県）
社会保険仲原病院（福岡県）
久留米大学（福岡県）
久留米大学医療センター（福岡県）
社会保険久留米第一病院（福岡県）
聖マリア病院（福岡県）
公立八女総合病院（福岡県）
大牟田市立総合病院（福岡県）
福岡県済生会大牟田病院（福岡県）
麻生飯塚病院（福岡県）
福岡市民病院（福岡県）
有田共立病院（佐賀県）
佐世保市立総合病院（長崎県）
長崎大学（長崎県）
光晴会病院（長崎県）
国立病院機構長崎医療センター（長崎県）
済生会熊本病院（熊本県）
熊本大学（熊本県）
健康保険人吉総合病院（熊本県）
大分県立病院（大分県）
大分赤十字病院（大分県）
国立病院機構大分医療センター（大分県）
国立病院機構別府医療センター（大分県）
中津市立中津市民病院（大分県）
大分県済生会日田病院（大分県）
小林市立病院（宮崎県）
宮崎県立延岡病院（宮崎県）
社会保険宮崎江南病院（宮崎県）
国立病院機構南九州病院（鹿児島県）
今給黎総合病院（鹿児島県）
潤愛会 鮫島病院（鹿児島県）
鹿児島大学（鹿児島県）
鹿児島厚生連病院（鹿児島県）
済生会川内病院（鹿児島県）
県民健康プラザ鹿屋医療センター（鹿児島県）
鹿児島県立薩南病院（鹿児島県）
浦添総合病院（沖縄県）
中頭病院（沖縄県）
ハートライフ病院（沖縄県）
琉球大学（沖縄県）
北部地区医師会病院（沖縄県）
広島赤十字・原爆病院（広島県）
松山赤十字病院（愛媛県）
防府消化器病センター 防府胃腸病院（山口県）
Other administrative information
Date of disclosure of the study information
| 2008 | Year | 08 | Month | 12 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
http://www.ncbi.nlm.nih.gov/pubmed/26037783
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2008 | Year | 02 | Month | 14 | Day |
Date of IRB
Anticipated trial start date
| 2008 | Year | 03 | Month | 01 | Day |
Last follow-up date
| 2010 | Year | 03 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2008 | Year | 08 | Month | 12 | Day |
Last modified on
| 2017 | Year | 01 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001593
